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ABSTRACT
Hepatocellular carcinoma (HCC) is a heterogeneous
condition, with multiple confounding factors making
patient assessment extremely complex. Tumor burden,
the presence of symptoms, liver function, and comor-
bidities must all be considered to ensure accurate pa-
tient assessment, thereby providing physicians with a
common language on which to base treatment decisions
and guide research. Although many staging classifica-
tions have been developed, there is no consensus on the
best classification to use. The Barcelona Clinic Liver
Cancer system is a promising candidate for a standard
western classification, because it has been externally
validated and is endorsed by the European Association
for the Study of the Liver and the American Association
for the Study of Liver Diseases. Similarly, the biomar-
ker-combined Japanese Integrated Staging (JIS)
score is the most promising candidate for a standard
Asia-Pacific classification, because it has been exter-
nally validated and shown to be superior to conven-
tional JIS. Because risk factors vary significantly by
region, so too does the predictive power of current
staging classifications; any standard global staging
classification would need to be validated in both west-
ern and Asia-Pacific patients. To date, no such glo-
bally validated classification exists. Findings from
scientific research have improved our understanding
of HCC and enabled us to refine current classifica-
tions. The role of tumor markers to predict survival
was recently reported, and -fetoprotein, lens culi-
naris agglutinin-reactive -fetoprotein, and des--
carboxyprothrombin have now been incorporated
into some classifications. Molecular markers have
also been linked with poor outcomes and will likely
play a role in future classifications. Although more
work is required, it is hoped that these and other on-
going research efforts will eventually enable the de-
velopment of a global staging classification. The
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INTRODUCTION
Hepatocellular carcinoma (HCC) is a heterogeneous condi-
tion with multiple variables that vary from region to region,
complicating diagnosis, prognosis, and treatment recom-
mendations. The presence of comorbidities is a common
confounding factor that can compromise liver function and
affect outcomes. For example, 80% of patients present with
liver cirrhosis [1] and 85.5% of patients are carriers of ei-
ther hepatitis B virus (HBV), which is particularly preva-
lent in Africa and Asia, or hepatitis C virus (HCV),
prevalent in western countries and Japan [2, 3]. The char-
acteristics of HCC also vary with geographic location. In
rural South Africa, HCC is commonly diagnosed at a more
advanced stage than in North America [4]. Because HBV is
often acquired at an early age in Africa and Asia, HCC may
also develop in younger patients and in the absence of liver
cirrhosis [5]. Conversely, in North America, many patients
have long-term liver cirrhosis and subsequently develop
HCC. Clinical presentation in these patients is therefore
dominated by complications of cirrhosis. These confound-
ing factors mean that multiple variables must be considered
when assessing patients with HCC.
The aims of HCC staging classifications are to: stratify
patients to determine their overall survival (OS) probability
prior to treatment, facilitate treatment, and enable objective
comparison among the outcomes of research studies. What
separates HCC from other solid tumors is that the presence
of chronic liver disease and cirrhosis affects OS and the
ability to treat this tumor. Therefore, liver disease is a very
important variable, together with the overall health of the
patient [6, 7]. In considering all these variables, it is hoped
that accurate and consistent assessment of all patients can
be achieved, thereby providing a common language for
physicians as well as the broader multidisciplinary team.
This, in turn, should facilitate appropriate treatment selec-
tion and ensure optimum patient management. However,
with 15 HCC staging classifications available, each mea-
suring a range of different factors and developed in differ-
ent patient populations, physicians are faced with the
complicated task of choosing which classification to use.
In this article, we review the major HCC staging classi-
fications used globally and examine the factors assessed, as
well as how each of the staging classifications was devel-
oped and validated. We also provide an overview of com-
parisons among various staging classifications reported in
the literature. The paper does not aim to assess the relative
values of individual classifications, nor to provide any en-
dorsement of one system over another. However, we sug-
gest possible areas for improvements that are necessary if
we are to achieve a globally applicable HCC staging
classification.
STAGING CLASSIFICATIONS IN HCC
The factors influencing the development of HCC and its
disease course vary considerably from region to region. As
a result, various staging classifications have been devel-
oped that take into account a range of factors (Table 1), and
although some classifications appear to be effective across
broad regions, such as western or Asia-Pacific patient pop-
ulations, others have been evaluated only in a single coun-
try. However, there is no globally applicable staging
classification, and thus no common language on which to
base treatment decisions and guide research.
Tumor–Node–Metastasis Staging System
The first staging classification for solid tumors was devel-
oped 50 years ago by the French surgeon Pierre Denoix
[8]. In 1968, his recommendations for various tumors were
compiled and published by the International Union Against
Cancer and the American Joint Committee on Cancer in the
first edition of the tumor–node–metastasis (TNM) staging
system. Since then, this staging classification has under-
gone several amendments, and the most recent, sixth edi-
tion, was published in 2003 [9, 10].
The TNM staging classification provides an assessment
of solid tumors based only on size and extent of invasion.
This is measured according to the size of the primary tumor
(T), presence of tumor in the regional lymph nodes (N), and
presence of metastatic spread beyond the lymph nodes (M).
Assessment of TNM staging can be prior to treatment (clin-
ical staging) or after surgery (pathologic staging) [8]. Clin-
ical staging is performed using imaging procedures, but in
patients with HCC, the presence of cirrhosis and/or swell-
ing of the lymph nodes as a result of chronic liver disease
may prevent accurate assessment. Pathologic staging is
therefore needed, but this may not be possible in the major-
ity of patients because very few undergo surgical therapies
that allow appropriate sampling.
The prognostic value of the sixth edition of the TNM
staging system was compared with three other staging clas-
sifications (the Okuda, Cancer of the Liver Italian Program
[CLIP], and Chinese University Prognostic Index [CUPI]
classifications) in 234 patients with HCC who underwent
curative resection at the Southwestern Hospital in China.
Both the Okuda and the TNM systems were better at strat-
ifying patients according to survival than the CLIP or CUPI
system. However, the TNM classification was also better
for predicting prognosis than the three other classifications,
and was significantly better than the CLIP score (p  .05)
[11]. The sixth edition of the TNM staging system also
proved to be more effective than six other classifications
(the Okuda, Barcelona Clinic Liver Cancer [BCLC], Japa-
nese Integrated Staging [JIS], CLIP, and Groupe d’Etude et
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de Traitement du Carcinome Hépatocellulaire [GRETCH]
classifications) at assessing prognosis in 163 patients with
HCC following resection in a retrospective study at a single
institution in Korea [12]. Those studies were limited to the
postsurgery setting, and evaluation in a larger sample size
and broader patient population is still required.
Okuda Classification
The Okuda classification was published in 1985 and was
the first staging system to include parameters related to tu-
mor size (50% versus 50% of the liver involved) and
liver function (albumin, ascites, bilirubin) [13]. Its ability to
predict prognosis according to treatment was evaluated as
part of a retrospective analysis among 850 patients treated
in three different institutes in Japan, with patients stratified
into three stages (I, not advanced; II, moderately advanced;
III, very advanced). These findings showed that surgically
treated patients had a longer survival time than medically
treated patients, and that medical treatment prolonged sur-
vival in stage II and stage III patients but not in stage I pa-
tients. However, because stage at diagnosis as well as the
available medical interventions have moved on since the
time this staging classification was developed, stratifying
patients to receive radical or palliative therapies using this
system alone would not be appropriate. Moreover, although
its simplicity makes it clinically attractive, its ability to pre-
dict prognosis is relatively modest [5]. Indeed, in a retro-
spective study in Canada, the Okuda classification failed to
identify two thirds of the 37 patients with a poor prognosis
who were identified by the CLIP criteria [14]. Furthermore,
in an evaluation of staging systems for HCC patients under-
going surgery, the Okuda system was not superior to TNM
staging [15].
CLIP Scoring
The CLIP scoring system was derived from a retrospective
analysis of 435 patients with HCC from 16 Italian institu-
tions and was published in 1998 [16]. Here, four indepen-
dent predictive factors of survival were identified (Child-
Pugh score, tumor morphology, -fetoprotein [AFP], and
Table 1. Key characteristics of various staging classifications available to assess the prognosis of patients with
hepatocellular carcinoma
Staging
classification
Variables measured
Year
published StudyTumor staging Liver function
Performance
status
Serum tumor
markers
CLIP Tumor morphology (uninodular
and extension 50%,
multinodular and extension
50%, massive or extension
50%), portal vein thrombosis
Child-Pugh No AFP 1998 CLIP Investigators
[16]
BCLC Tumor size, number of nodules,
portal vein thrombosis
Child-Pugh, bilirubin, portal
hypertension
PST No 1999 Llovet et al. [24]
GRETCH Portal vein thrombosis Bilirubin, alkaline
phosphatase
Karnofsky AFP 1999 Chevret et al. [34]
U.S. nomogram Resection margin status, tumor
size 5 cm, satellite lesions,
vascular invasion
No Age, operative
blood loss
AFP 2008 Cho et al. [45]
Okuda Tumor size (/50% of liver) Ascites, albumin, bilirubin No No 1985 Okuda et al. [13]
CUPI TNM fifth edition Ascites, bilirubin, alkaline
phosphatase
Presence of
symptoms
AFP 2002 Leung et al. [37]
JIS Japanese TNM fourth edition Child-Pugh No No 2003 Kudo et al. [23]
bm-JIS Japanese TNM fourth edition Child-Pugh No AFP, AFP-L3, DCP 2008 Kitai et al. [39]
SLiDe Stage and liver damage
categories from the Japanese
TNM fourth edition
No No DCP 2004 Omagari et al. [41]
Tokyo Size and number of tumors Albumin, bilirubin No No 2005 Tateishi et al. [42]
BALAD No Albumin, bilirubin No AFP, AFP-L3, DCP 2006 Toyoda et al. [44]
ALCPS Tumor size, portal vein
thrombosis, lung metastases
Ascites, Child-Pugh, alkaline
phosphatase, bilirubin, urea
Abdominal pain,
weight loss
AFP 2008 Yau et al. [46]
Abbreviations: AFP, -fetoprotein; AFP-L3, lens culinaris agglutinin-reactive AFP; ALCPS, Advanced Liver Cancer
Prognostic System; BALAD, bilirubin, albumin, AFP-L3, AFP, DCP; BCLC, Barcelona Clinic Liver Cancer; bm-JIS,
biomarker-combined JIS; CLIP, Cancer of the Liver Italian Program; CUPI, Chinese University Prognostic Index; DCP,
des--carboxyprothrombin; GRETCH, Groupe d’Etude et de Traitement du Carcinome Hépatocellulaire; JIS, Japanese
Integrated Staging; PST, performance status test; SLiDe, Stage, Liver damage, DCP; TNM, tumor–node–metastasis.
From Meier V, Ramadori G. Clinical staging of hepatocellular carcinoma. Dig Dis 2009;27:131–141. Reproduced with
permission from S. Karger AG, Basel, Switzerland.
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portal vein thrombosis), and a simple linear scoring system
(0, 1, or 2) was assigned to the covariates in order to give
patients a total score of 0–6. This scoring system was sub-
sequently validated by the same group in a prospective trial
of 196 patients with HCC and cirrhosis [17] and was also
shown to be effective in predicting survival among a group
of 145 patients in the Middle East [18] and in 662 Japanese
patients [19]. However, whereas the median survival time
associated with each CLIP score (0–6) appears to be simi-
lar between patients included in the prospective validation
conducted by the founding group and those included in the
study conducted in the Middle East [18, 20], the median
survival times reported for Japanese patients were higher
for all CLIP scores [19], and it has been suggested that these
findings could compromise the external validation of the
CLIP scoring system [21].
In a comparison of the CLIP, BCLC, and Okuda staging
systems using a pooled database from two randomized tri-
als of French patients with mainly alcoholic HCC, the per-
formances of all three systems were disappointing;
different systems performed differently according to pa-
tient populations and for individual prognostic factors.
None clearly emerged as an unquestionable reference [22].
However, for all statistics, the CLIP system had better prog-
nostic ability. The authors concluded that the CLIP staging
seems to be most adapted to the palliative setting and that it
could be improved by associating World Health Organiza-
tion performance status.
A number of limitations of the CLIP scoring system
have been reported [23]. First, the tumor morphology cate-
gories used may be too general to be globally applicable,
particularly in countries such as Japan, where more patients
are diagnosed with very small solitary tumors, largely be-
cause of the established screening programs in place. Sec-
ondly, although patient populations with different CLIP
scores appear to be well discriminated from each other,
there is no clear difference among patient populations with
CLIP scores of 4–6 [17]. Indeed, in the prospective valida-
tion of this scoring system performed by the founding group
[20], they grouped patients with a CLIP score of 4–6 into
one group. Finally, all studies evaluating the CLIP score re-
ported to date show that a high proportion of patients are
categorized as CLIP score 0–2, suggesting poor stratifica-
tion ability with this system.
Taken together, these findings suggest that, although the
CLIP scoring system is associated with a good prognostic
ability, this staging system may not be sensitive enough to
be applicable to all patient populations and cannot easily be
applied to a patient’s management.
BCLC Staging
The BCLC staging classification was proposed by Llovet
and colleagues in 1999 [24]. One of the most important ob-
servations for the development of the BCLC staging system
came from the follow-up of patients with nonresectable and
nontransplantable HCC who were randomized to placebo in
two different clinical trials [25]. In that study, the multivar-
iate analysis identified performance status, constitutional
syndrome, vascular invasion, and extrahepatic spread as in-
dependent predictors for mortality. The authors showed
that the 1-, 2-, and 3-year survival rates for the 48 patients
without predictors of mortality (i.e., intermediate stage)
were 80%, 65%, and 50%, respectively, and these were
29%, 16%, and 8% in the 54 patients with at least one ad-
verse factor (i.e., advanced stage). This has been externally
validated [26]. This allowed patients to be divided into dif-
ferent categories based on tumor stage (tumor size, number
of nodules, and presence of portal vein thrombosis), liver
function (Child-Pugh score, portal hypertension, bilirubin
level), physical status (performance status test), and cancer-
related symptoms. Furthermore, four categories were cre-
ated (A, early; B, intermediate; C, advanced; D, end-stage
disease). It is also unique in that it is the only system that
provides treatment recommendations for each of the as-
signed stages based on the best treatment options currently
available. The BCLC staging classification has been exter-
nally validated in the U.S. [6], Europe [27, 28], and Taiwan
[29] and has demonstrated superior survival stratification
and prognosis prediction over a range of other classifica-
tions, including the Okuda, TNM, CLIP, GRETCH, CUPI,
and JIS classifications [28, 30]. Moreover, BCLC staging is
endorsed by both the European Association for the Study of
the Liver (EASL) [5] and the American Association for the
Study of Liver Diseases (AASLD) [31], and it is emerging
as a standard staging classification in western populations
[32]. The most important aspect of this staging classifica-
tion is that it is linked to an evidence-based treatment algo-
rithm and can easily be used in a clinical setting. However,
it should be noted that, in a study investigating which of the
available staging systems was the most informative for the
medical oncologist [33], the BCLC system was found to be
less informative than the GRETCH and CLIP classifica-
tions when ranked using a concordance index, a likelihood
ratio, and the Akaike information criterion. However, that
study mostly evaluated patients with advanced tumors and
may not be generally applicable.
GRETCH Scoring
The GRETCH scoring system was based on findings from a
prospective study among 761 patients from 24 western
medical centers and was published in 1999 [34]. The aim of
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the study was to compile a classification system for predict-
ing survival among these patients using a multivariate Cox
model. Five prognostic factors were selected (Karnofsky
index 80%, bilirubin 50 mol/l, alkaline phosphatase
2 the upper limit of normal, AFP 25 g/l, and ultra-
sonographic portal vein obstruction) in order to divide pa-
tients in the study training sample (n  506) into three
prognostic classification groups (A, B, C). The 1-year sur-
vival rates associated with these three groups were derived
(72%, 34%, and 7% for groups A, B, and C, respectively)
and independently validated in the study test sample (79%,
31%, and 4% for groups A, B, and C, respectively; n 
255). This system has not been validated in nonwestern pa-
tient populations. Furthermore, because this system origi-
nated from a multivariate analysis, it may not be
reproducible or easily used in clinical practice.
Liver Cancer Study Group of Japan
TNM Staging
In 1965, the Liver Cancer Study Group of Japan (LCSGJ)
started a nationwide registration of clinicopathologic and
prognostic data from patients with primary liver cancer, and
using data collected in this database they introduced the
Japanese version of the TNM staging system in 1983. This
has subsequently undergone a number of revisions, and in
2007 the LCSGJ evaluated data from their database of
63,736 patients with primary liver cancer, 13,772 of whom
underwent curative resection, in order to present evidence
to develop and validate this staging classification [35].
Based on univariate and multivariate survival analyses,
they selected three factors (vascular or bile duct invasion,
tumor diameter 2 cm versus 2 cm, and number of tu-
mors—single versus multiple), and classified patients as
T1–T4 based on the number of adverse factors present (pa-
tients with none were considered T1, those with one were
T2, those with two were T3, and those with three were T4).
Significant survival differences were demonstrated among
patients in each of the four assigned stages, with 5-year sur-
vival rates of 70% (T1), 58% (T2), 41% (T3), and 24% (T4)
(p  .0001). A potential weakness of the LCSGJ staging
system is that it assumes equal weight for growth pattern,
size, and vascular or bile duct invasion. No external valida-
tion has been reported to date.
The Vauthey Simplified Staging System
In 2002, Vauthey and colleagues evaluated the efficacy of
using the TNM’s T categories to stratify patients according
to survival and assessed a range of independent prognostic
factors among 557 patients undergoing resection [36]. In-
dependent predictors of death in that study were major vas-
cular invasion, microvascular invasion, severe fibrosis/
cirrhosis of the liver, multiple tumors, and tumors 5 cm.
Based on these findings, Vauthey and colleagues proposed
a simplified model of patient stratification using vascular
invasion, tumor number and size, and the effect of fibrosis
on survival. Patients were divided into three stages (I, II,
III) and these were associated with a significant survival
difference, with 5-year survival rates of 55% (I), 37% (II),
and 16% (III) (p  .001) [36]. This is limited to postsurgery
patients and has not been externally validated.
CUPI Score
The CUPI score was developed at the Chinese University in
Hong Kong and was published in 2002 [37]. In that study,
19 potential prognostic factors were evaluated in a multi-
variate analysis using a Cox regression model among 926
Chinese patients, mostly with HBV-associated HCC. From
this, five additional prognostic factors (asymptomatic dis-
ease at presentation, AFP, total bilirubin, alkaline phospha-
tase, and ascites) were added to the fifth edition of the TNM
staging classification. Patients were divided into three risk
groups (high, medium, and low risk for dying within 3
months), and highly significant differences in survival were
observed among these groups (p  .00001). Findings from
that study also showed that the CUPI system was better at
classifying patients into different risk groups than the TNM
staging system alone, or the Okuda or CLIP scoring sys-
tems, although the authors advise that validation across
broader patient populations is needed. In a more recent
study, the CUPI staging system was compared with the
Okuda, CLIP, and sixth edition of the TNM staging systems
among 234 Chinese patients who underwent resection [11].
The authors concluded that the TNM sixth edition was su-
perior in discriminating survival among patients stratified
into different stages, and suggested that a possible limita-
tion of the CUPI score is that it is based on the fifth edition
of the TNM. The CUPI system has not been externally
validated.
JIS Score
In 2003, an integrated prognostic classification system was
published by Kudo and colleagues [23]. This scoring sys-
tem combines the Japanese TNM staging (stages I, II, III,
and IV are converted to scores 0, 1, 2, and 3, respectively)
and the conventional Child-Pugh (stages A, B, and C are
converted to scores 0, 1, and 2, respectively) to produce a
JIS score of 0–5. This scoring system was evaluated in 722
Japanese patients with HCC, and statistically significant
differences were observed in the survival curves among JIS
scores of 0–3, but not among scores of 4–6 [23]. It has been
noted that the JIS system may be limited in its ability to
stratify patients with advanced scores because it uniformly
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assigns tumor stage and liver function [35]. However, this
system has been externally validated [38] and it appears to
be one of the most promising candidates for a standard clas-
sification system across the Asia-Pacific region. However,
it has not been validated in a western patient population.
The JIS staging classification was further modified by
Kitai and colleagues to include evaluation of three tumor
markers for HCC, namely AFP, lens culinaris agglutinin-
reactive AFP (AFP-L3), and des--carboxyprothrombin
(DCP). This biomarker-combined JIS (bm-JIS) scoring
system was evaluated in 1,924 patients with HCC, and find-
ings published in 2008 showed that the bm-JIS scoring sys-
tem had superior stratification ability and was a better
predictor of prognosis than the conventional JIS scoring
system [39]. This system has now been externally validated
but still requires validation in a western patient population
[40].
STAGE, LIVER DAMAGE, DCP STAGING SYSTEM
The stage, liver damage, DCP (SLiDe) staging system was
established in 2004 when Omagari and colleagues evalu-
ated a range of prognostic markers in univariate and multi-
variate analyses using the medical records of 177 patients
with HCC from the Nagasaki University School of Medi-
cine in Japan [41]. In that analysis, only the “stage” and
“liver damage” categories from the fourth edition of the
Japanese TNM staging classification, as well as serum
DCP, remained significant prognostic factors of survival.
Thus, in the SLiDe staging system, patients were assigned a
score based on these covariates (0, 1, 2, or 3), and findings
from this retrospective analysis showed that there was clear
discrimination among the survival curves plotted for pa-
tients with different SLiDe scores [41]. Although the au-
thors concluded that this is a useful system to assess the
prognosis of patients, they also advised that, because the
Japanese TNM staging classification must be used, which
includes some parameters that are not routinely assessed in
other parts of the world, external validation in a large pa-
tient population would be needed before this system could
be adopted.
Tokyo Classification
In a study published in 2005, 403 patients with HCC treated
with percutaneous ablation at the University of Tokyo were
used as a training sample to identify prognostic factors and
to develop the Tokyo score based on four factors (albumin,
bilirubin, and size and number of tumors) [42]. Prognostic
factors were then analyzed in a testing sample of 203 pa-
tients with HCC who had undergone resection. Clear sur-
vival differences were demonstrated among Tokyo scores,
with 5-year survival rates of 78.7% (0), 62.1% (1), 40.0%
(2), 27.7% (3), and 14.3% (4–6). This system was validated
by the same group, whereby it showed similar predictive
ability to the CLIP scoring system and superior predictive
ability to the BCLC staging classification. However, in a
comparison of the JIS, BCLC, and Tokyo classifications in
a Japanese cohort of HCC patients mainly with early-stage
disease treated with radical therapy, the JIS score provided
the best prognostic stratification [43]. Further external val-
idation of the Tokyo classification in different patient pop-
ulations is needed.
Bilirubin, Albumin, AFP-L3, AFP, DCP Score
The bilirubin, albumin, AFP-L3, AFP, DCP (BALAD)
score, published by Toyoda and colleagues in 2006 [44], is
a staging classification devised using only serum markers
(bilirubin, albumin, AFP-L3, AFP, DCP). This scoring sys-
tem, calculated as the sum of the remnant liver function
score (i.e., albumin and bilirubin scoring, as devised by
Tateishi and colleagues [42]) plus the tumor progression
score (measured as the number of elevated tumor markers),
was evaluated among 2,600 patients with HCC from five
institutions. Patients were divided into six groups on the ba-
sis of the five laboratory values, with clear survival differ-
ences observed among the groups. Toyoda and colleagues
also compared the BALAD scoring system with two stag-
ing classifications that consider both tumor progression and
liver function factors (the JIS and CLIP classifications).
They demonstrated that all three systems showed compara-
ble prediction and discrimination of patient survival [44].
However, in a study comparing the BALAD scoring system
with the JIS and bm-JIS systems conducted by Kitai and
colleagues [40], there were significant differences between
the BALAD and bm-JIS scores and the BALAD and JIS
scores, even though all three systems effectively predicted
patient survival. The authors concluded that the bm-JIS
classification was superior to both the JIS and BALAD
scoring systems, especially among patients with a good
prognosis [40].
A U.S.-Based Prognostic Nomogram
In a recent study published in 2008, 184 patients with HCC
undergoing resection at a single institution in the U.S. were
classified according to eight staging classifications [45].
The ability of these classifications to predict postoperative
survival was evaluated in randomly selected pairs using
Harrell’s concordance index. A novel nomogram was then
developed using age, AFP level, operative blood loss, sur-
gical resection margin status, tumor size, satellite lesions,
and vascular invasion. Using this nomogram, survival
could be predicted with a higher concordance level between
randomly tested pairs than with any of the eight conven-
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tional classification systems tested (concordance index of
0.74 for the nomogram versus 0.54–0.59 for the eight stag-
ing classifications tested) [45]. That analysis relied on a sin-
gle institutional data set of HCC patients, which may
introduce selection bias. These findings have not yet been
externally validated and this nomogram is not currently
used clinically.
Advanced Liver Cancer Prognostic System Score
Because patients with advanced HCC who are not amena-
ble to locoregional therapy are candidates for inclusion in
clinical trials providing they have a good 3-month survival
probability, the advanced liver cancer prognostic system
(ALCPS) scoring system was devised to objectively predict
the 3-month survival probability among these patients [46].
In a study by Yau and colleagues published in 2008, the
prognostic significance of a range of factors was evaluated
by univariate and multivariate Cox regression analyses in a
training set of 1,109 patients. From this, 11 significant
prognostic factors were identified (ascites, abdominal pain,
weight loss, Child-Pugh score, alkaline phosphatase, total
bilirubin, AFP, urea level, tumor size, portal thrombosis,
and lung metastases) and assessed to provide patients with a
score of 0–39 (with a higher score being associated with a
lower survival probability). These scores were then divided
into three groups in order to categorize patients as having a
good (ALCPS score, 0 – 8), intermediate (ALCPS score,
9–15), or poor (ALCPS score, 16–39) probability of sur-
viving at least 3 months. Patients assessed in the training set
were stratified according to their ALCPS score, and
Kaplan–Meier estimates for each group showed clear sur-
vival differences, with median OS times of 7.9 months, 3.2
months, and 1.4 months for the good, intermediate, and
poor groups, respectively. In the same study, ALCPS scores
were subsequently assessed in a validation sample of 320
patients, and outcomes very similar to the testing sample
were reported (median OS time, 7.5 months, 3.2 months,
and 1.2 months for the good, intermediate, and poor groups,
respectively) [46]. Moreover, patients in the validation set
were also assessed by the Okuda and CLIP scoring systems,
and the discriminatory ability of each prognostic scoring
system, assessed by constructing receiver-operating char-
acteristic curves, showed that the ALCPS scoring system
had significantly better predictive power than either the
Okuda (area under the curve [AUC], 0.77 versus 0.66 for
the ALCPS and Okuda classifications, respectively; p 
.001) or CLIP (AUC, 0.77 versus 0.71 for ALCPS and CLIP
classifications, respectively; p  .002) scoring systems. It
must be noted that the data set used to construct ALCPS
system was from a single institute, consisting predomi-
nantly of an HBV-prevalent Chinese population. It is not
known whether ALCPS system can be applied to other pop-
ulations.
SUMMARY OF STAGING CLASSIFICATIONS: WHAT
IS THE BEST SYSTEM AVAILABLE?
The number of staging classifications for HCC has in-
creased in recent years, and more recent classifications
have demonstrated better prognostic ability than earlier sys-
tems (Table 2). However, improvements are still ongoing
and there is no agreement on a standard classification that
could be used globally.
Earlier classifications, such as the TNM staging system,
only considered tumor staging factors, and as such their
prognostic ability was regarded as limited. Given the im-
pact that HCC and common comorbidities such as cirrhosis,
HBV, and HCV have on liver function, most classifications
now consider both tumor staging factors and liver function
to predict patient outcomes. In recent years, there has been
increasing interest in the role of biomarkers to predict survival.
However, although adding further parameters to staging clas-
sifications may help improve the accuracy of these systems, it
is important to ensure we do not create systems that are overly
complex, because this may limit their clinical utility.
One of the goals of staging systems today is to provide
an evidence-based treatment guide [6, 7, 21]. Although all
staging classifications have been designed to predict prog-
nosis, the BCLC staging classification is currently the only
system that also provides a recommended treatment algo-
rithm linked to each stage of disease [24]. However, the
main strength of the BCLC staging system is that the four
categories of patients have distinct natural histories and it is
easy to apply clinically. Whether the treatment that is linked
to each BCLC stage is used will depend on factors such as
institutional strength and patient selection.
Because most patients with HCC present with advanced
disease, many of the staging classifications, including the
CUPI, CLIP, GRETCH, and ALCPS classifications, were
constructed among this patient group [16, 34, 37, 46]. This
could represent a limitation of these systems in terms of the
accuracy of predicting prognosis in patients with earlier-
stage HCC. Thus, systems such as the Japanese TNM stag-
ing system, which was constructed based on a large
database of clinicopathologic data from patients at all
stages of disease, including 13,772 who were eligible for
curative resection, may be more appropriate for assessing
patients with earlier-stage disease [35].
Because there are significant regional differences in
HCC in terms of tumor morphology and the presence of co-
morbidities, which affect the disease course and ultimately
patient prognosis, a staging classification needs to be vali-
dated in both western and Asia-Pacific patient populations
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before it can be considered globally applicable. Unfortu-
nately, none of the staging classifications currently avail-
able has been validated in all these patient populations, and
as such none can be recommended for worldwide use.
However, the BCLC system has been validated in the U.S.,
Europe, and Taiwan, and it is the only system that has so far
been validated in three continents.
A number of studies have been conducted to compare
various staging classifications in the same patient popula-
tion (Table 3), and findings suggest that the staging classi-
fication to show superior predictive power depends on the
region. In western patient populations, the BCLC staging
system appears to be superior based on findings in separate
studies (two conducted in Italy, one in Taiwan, and one in
North America) [6, 28, 29, 30]. In Japan, Kudo and col-
leagues demonstrated that the JIS scoring system was superior
to the CLIP classification among 4,525 patients with HCC
[38]. However, it has not been validated outside Japan.
Taken together, these findings show that, as our knowl-
edge of this complex disease improves, staging classifica-
tions continue to be refined. As more is known about the
pathogenesis of HCC and molecular markers, better staging
systems will be developed.
CONCLUSIONS
HCC is a heterogeneous condition, with multiple confound-
ing factors making assessment of these patients extremely
complex. Many elements, including tumor burden, the
presence of symptoms, liver function, comorbidities, and
the likely effect of treatment, need to be considered in order
to ensure accurate and consistent assessment of all patients,
thereby providing physicians with a common language on
which to base treatment decisions and guide research. This
review examines each classification but does not assess
their relative value. Although many different staging clas-
sifications have been developed and there is currently no
consensus on the best classification to use, the BCLC stag-
ing classification is emerging as a promising candidate for a
standard classification in western regions, because it has
been externally validated [6, 28, 30] and it is also endorsed
Table 2. Comparison of externally validated staging classifications available for hepatocellular carcinoma
Staging
classification
Region
developed
n of
patients
Validation
studies
Comparator staging
classifications used
n of
patients Main outcomes
CLIP [16] Italy 435 Italy [17, 20] CLIP, Okuda 196 CLIP demonstrated greater survival
predictive power than Okuda
Middle East [18] CLIP, Okuda 145 CLIP was more reliable than
Okuda in predicting survival
Japan [19] CLIP, TNM, Okuda 662 CLIP had the highest stratification
ability. Median survival times
greater in this study than two
previous studies
BCLC [24] Spain 239 USA [6] Okuda, TNM, BCLC,
CLIP, GRETCH,
CUPI, JIS
239 BCLC demonstrated the best
independent predictive power for
survival
Italy [28] Okuda, CLIP, Child-
Pugh, BCLC, CUPI
187 BCLC was the best prognostic
system among patients suitable for
resection or ablation
Italy [30] Okuda, TNM, BCLC,
CLIP, GRETCH,
CUPI, JIS
112 BCLC showed superior
discriminatory power among a
group of patients who underwent
radiofrequency ablation therapy
JIS [23] Japan 722 Japan [38] JIS, CLIP 4,525 The prognostic predictive power of
JIS was superior to that of CLIP
JIS score was simple to obtain and
remember
bm-JIS [39] Japan 1,924 Japan [40] JIS, bm-JIS, BALAD 1,173 bm-JIS score showed good
stratification ability and was
superior in predicting prognosis,
especially among patients with a
good prognosis
Abbreviations: BALAD, bilirubin, albumin, lens culinaris agglutinin-reactive -fetoprotein, -fetoprotein,
des--carboxyprothrombin; BCLC, Barcelona Clinic Liver Cancer; bm-JIS, biomarker-combined JIS; CLIP, Cancer of the
Liver Italian Program; CUPI, Chinese University Prognostic Index; GRETCH, Groupe d’Etude et de Traitement du
Carcinome Hépatocellulaire; JIS, Japanese Integrated Staging; TNM, tumor–node–metastasis.
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by both the EASL [5] and the AASLD [31]. However, be-
cause risk factors vary significantly from region to region,
any standard global staging classification needs to be vali-
dated in both western and Asia-Pacific patient populations;
to date, no such staging classification exists.
Continued research efforts have improved our under-
standing of this complex disease, which has allowed us to
refine staging classifications and improve our therapeutic
approach. In recent years, a significant amount of research
has reported on the role of tumor markers to predict survival
in HCC, and the markers AFP, AFP-L3, and DCP have now
been incorporated into some staging classifications. In ad-
dition, molecular markers such as hepatocyte growth factor,
vascular endothelial growth factor, and transforming
growth factor  1 have been linked with poor outcomes in
HCC patients [47], and so may play a role in helping us to
further improve staging classifications. In addition to the
added information that tumor and molecular markers bring,
data from ongoing studies may contribute. The Global In-
vestigation of therapeutic DEcisions in hepatocellular car-
cinoma and Of its treatment with sorafeNib (GIDEON)
study is a large global, noninterventional study of patients
with unresectable HCC receiving sorafenib (Nexavar;
Onyx Pharmaceuticals, Inc., Emeryville, CA; Bayer
HealthCare Pharmaceuticals, Inc., Wayne, NJ; Bayer
Schering Pharma AG, Berlin, Germany) therapy. That
study will collect details of local, regional, and global meth-
ods of patient evaluation, diagnosis, and follow-up, and as-
sess comorbidities and their influence on treatment and
outcome. Information collected in this database may be of
value in further refining current staging classifications.
However, further research efforts are needed for us to gain
a full understanding of the factors that affect the prognosis
of patients with HCC.
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